Clinical trial
Continuation Booster Trial After a Vaccine Combining Tyrosinase/GP100/MART-1…
NCT00184067 · University of Southern California, Other · Terminated
Key facts
| NCT number | NCT00184067 |
|---|---|
| Title | Continuation Booster Trial After a Vaccine Combining Tyrosinase/GP100/MART-1 Peptides Emulsified With Montanide ISA 51 With or Without GM-CSF for Patients With Melanoma |
| Official title | A Randomized Phase II Continuation Booster Trial After a Vaccine Combining Tyrosinase/GP100/MART-1 Peptides Emulsified With Montanide ISA 51 With or Without GM-CSF for Patients With Resected Stages IIB/C, III, and IV Melanoma |
| Lead sponsor | University of Southern California, Other |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Melanoma |
| Intervention type | Biological |
| Interventions | Montanide ISA 51 |
| Enrollment | 23 |
| Start date | May 1, 2004 |
| Primary completion | Apr 1, 2007 |
| Completion | Sep 1, 2009 |
| First posted | Sep 16, 2005 |
| Last update posted | May 21, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: